Volume 5.02 | Jan 17

Mammary Cell News 5.02 January 17, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Suppression of miRNA-708 by Polycomb Group Promotes Metastases by Calcium-Induced Cell Migration
Scientists identified miR-708 being transcriptionally repressed by polycomb repressor complex 2-induced H3K27 trimethylation in metastatic breast cancer. miR-708 targets the endoplasmic reticulum protein neuronatin to decrease intracellular calcium level, resulting in reduction of activation of ERK and FAK, decreased cell migration, and impaired metastases. [Cancer Cell] Abstract | Press Release

Free Wallchart | Assays for Human Mammary Stem and Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Inhibition of Triple-Negative Breast Cancer Models by Combinations of Antibodies to EGFR
Breast tumors lacking expression of human epidermal growth factor receptor 2 and the estrogen and the progesterone receptors (triple-negative breast cancer; TNBC) are more aggressive than other disease subtypes, and no molecular targeted agents are currently available for their treatment. Because TNBC commonly displays EGF receptor (EGFR) expression, and combinations of monoclonal antibodies to EGFR effectively inhibit other tumor models, scientists addressed the relevance of this strategy to treatment of TNBC. [Proc Natl Acad Sci USA] Abstract

High Throughput Kinase Inhibitor Screens Reveal Tribbles Homolog 3 and MAPK-ERK/TGFβ Pathways as Fundamental Notch Regulators in Breast Cancer
Expression of the Notch ligand Jagged 1 and Notch activation promote poor-prognosis in breast cancer. Scientists used high throughput screens to identify elements responsible for Notch activation in this context. Chemical kinase inhibitor and kinase-specific small interfering RNA libraries were screened in a breast cancer cell line engineered to report Notch. [Proc Natl Acad Sci USA] Abstract

A Requirement for Nedd9 in Luminal Progenitor Cells Prior to Mammary Tumorigenesis in MMTV-HER2/ErbB2 Mice
Overexpression of the NEDD9/HEF1/Cas-L scaffolding protein is frequent, and drives invasion and metastasis in breast, head and neck, colorectal, melanoma, lung and other types of cancer. The authors examined the consequences of genetic ablation of Nedd9 in the MMTV-HER2/ERBB2/neu mouse mammary tumor model. [Oncogene] Abstract | Press Release

Induction of Cells with Cancer Stem Cell Properties from Nontumorigenic Human Mammary Epithelial Cells by Defined Reprogramming Factors
Investigators demonstrated that the introduction of defined reprogramming factors (OCT4, SOX2, Klf4 and c-Myc) into MCF-10A nontumorigenic mammary epithelial cells, followed by partial differentiation, transforms the bulk of cells into tumorigenic CD44+/CD24low cells with cancer stem cell properties. [Oncogene] Abstract

CEACAM-1 Negatively Regulates Granulocyte Colony-Stimulating Factor Production by Breast Tumor Associated Macrophages that Mediate Tumor Angiogenesis
Since macrophages are associated with a poor prognosis in breast cancer, but play important roles in normal breast, the authors hypothesized that carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM-1) down-regulation would lead to tumor promotion under inflammatory conditions. [Int J Cancer] Abstract

Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
Researchers studied and characterized the mechanisms associated with sensitivity and resistance to elisidepsin treatment in a broad panel of tumor cell lines from breast and pancreas carcinomas, focusing on different factors involved in epithelial-mesenchymal transition and the use of HER family receptors in predicting the in vitro drug response. [PLoS One] Full Article

Syndecan-1 Modulates Beta-Integrin- and IL-6-Dependent Functions in Breast Cancer Cell Adhesion, Migration and Resistance to Irradiation
Researchers evaluated the potential role of Syndecan-1 in modulating matrix-dependent breast cancer cell migration in the presence of Interleukin-6 (IL-6), and a potential involvement in resistance to irradiation in vitro. [FEBS J] Abstract

CLINICAL RESEARCH

Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine as First-Line Treatment for HER2-Negative Metastatic Breast Cancer: Interim Efficacy Results of the Randomized, Open-Label, Non-Inferiority, Phase III TURANDOT Trial
Randomized Phase III trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. Researchers compared the efficacy of the two regimens. [Lancet Oncol] Abstract

Bias in Reporting of End Points of Efficacy and Toxicity in Randomized, Clinical Trials for Women with Breast Cancer
Phase III randomized, clinical trials (RCTs) assess clinically important differences in end points that reflect benefit to patients. Researchers evaluated the quality of reporting of the primary end point and of toxicity in RCTs for breast cancer. [Ann Oncol] Full Article | Press Release

Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video

REVIEWS
Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer
This review provides a unifying perspective for the diverse effects of progesterone across human tissues and diseases. [Endocr Rev] Abstract
INDUSTRY NEWS

Advanomics Corporation, the Parent Company of Sunshine Biopharma, Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer Compound
Advanomics Corporation announced that it has filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Adva-27a is a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro. [Sunshine Biopharma Inc.] Press Release

Atossa Genetics and Clarity Women’s Health Announce U.S. Launch of the ForeCYTE Breast Health Test
Atossa Genetics and Clarity Women’s Health announced the launch of the ForeCYTE Breast Health Test. The patented ForeCYTE Breast Health Test is designed for the early detection of precancerous breast conditions and the determination of the future risk of breast cancer, using a clinically validated algorithm including family history, personal reproductive history and breast cytopathology. [Atossa Genetics, Inc.]
Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Cold Spring Harbor – Cancer Biology & Therapeutics
April 23-27, 2013
Cold Spring Harbor, United States


Visit
our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position/PhD Student – Resistance to Anti-Cancer Drug Therapy (The Netherlands Cancer Institute)

Laboratory Technician/Manager Position – MicroRNA Cancer Biology (Thomas Jefferson University)

Postdoctoral Position –  Impact of Ubiquitin-Proteasome Pathway in Genome Stability and Breast Cancer (University of Pittsburgh)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Bioinformatics Position in Cancer Research (San Raffaele Scientific Institute)

Postdoctoral Research Assistant – Clonal Expansion and Progression of Ductal Carcinoma In Situ (Barts Cancer Institute)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us